Loss narrows sharply. Lexicon Pharmaceuticals reported a loss of $0.04 per share for Q4 2025, narrowing 55.6% from the $0.09 per share loss in the year-ago quarter. The biotechnology company posted a net loss of $15.5 million for the quarter, with operating losses of $14.8 million partially offset by gross profit of $5.3 million.
Revenue collapses year-over-year. Q4 revenue totaled $5.5 million, down 79.3% from the prior-year quarter. Cost of revenue remained minimal at $201 million, suggesting the company maintained strong gross margins despite the sharp revenue decline. The stock traded flat at $1.61 following the release, with volume of 2.4 million shares.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post LXRX Reports Mixed Q4 Results: Loss Improves to $0.04 Per Share But Revenue Crashes 79% YoY first appeared on AlphaStreet News.
